TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Phase 2 Completed 23 enrolled H. Lee Moffitt Cancer Center and Research Institute

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to find out if the combination of TAS 102 and Ramucirumab is safe and effective in patients with advanced, refractory gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Timeline

Start: 2018-12-20
Primary completion: 2022-01-19
Completion: 2024-05-31

Publications

Kim DW, Kim RD, Jimenez MM, Kim Y, Mehta R. A phase II study of trifluridine/tipiracil in combination with ramucirumab in advanced, refractory gastric, or gastroesophageal junction adenocarcinomas. Oncologist. 2025 Dec 1;30(12):oyaf303. doi: 10.1093/oncolo/oyaf303.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ramucirumab	Monoclonal antibody	8 mg/kg	Intravenous
Subject	TAS-102	Small molecule	35 mg	—

TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Summary

Timeline

Publications

Drugs

Indications